| Texto completo | |
| Autor(es): |
Santos, Gabrielle de Mello
;
Saldanha, Artur
;
Orsi, Fernanda Andrade
Número total de Autores: 3
|
| Tipo de documento: | Artigo Científico |
| Fonte: | Clinical Immunology; v. 255, p. 8-pg., 2023-09-09. |
| Resumo | |
Systemic autoimmune diseases are characterized by increased production of type I interferon (IFN-1) and upregulation of IFN-1-inducible genes, suggesting an important role of the IFN-1 pathway in their pathogenesis. Recent studies have demonstrated increased IFN-1 expression in both primary and secondary antiphospholipid syndrome (APS), along with increased toll-like receptor type 9 activity and plasmacytoid dendritic cell function. The increasing knowledge of the association between IFN-1 and APS pathology may provide a rationale for conducting clinical trials to assess the efficacy of IFN-1-targeting drugs in reducing APS-related complications. In this narrative review, we summarize the current knowledge on the role of IFN-1 in APS pathogenesis, explore its clinical implications, and examine the existing evidence regarding therapeutic options that have been investigated to date. (AU) | |
| Processo FAPESP: | 20/12630-2 - Contribuição das redes extracelulares de neutrófilos (NETs) e da ativação plaquetária para a imunotrombose na COVID-19 e efeito inibitório de substâncias que aumentam os níveis intracelulares dos nucleotídeos cíclicos |
| Beneficiário: | Fernanda Loureiro de Andrade Orsi |
| Modalidade de apoio: | Auxílio à Pesquisa - Regular |